nature.com search

Loading Filters

Showing 1–32 of 32 results

Loading Filters

News | 15 May 2020
Biotech companies prepare for COVID-19 downturn
- Melanie Senior
Nature Biotechnology 38 , 663–664

Rights & permissionsfor article Biotech companies prepare for COVID-19 downturn . Opens in a new window.
Special Features | 7 April 2020
Europe’s biotech renaissance
- Melanie Senior
Nature Biotechnology 38 , 408–415

Rights & permissionsfor article Europe’s biotech renaissance . Opens in a new window.
News | 7 March 2013
Amgen fined $762 million
- Melanie Senior
Nature Biotechnology 31 , 182–182

Rights & permissionsfor article Amgen fined $762 million . Opens in a new window.
News | 8 October 2019
Deerfield builds NYC campus to support life sciences startups
- Melanie Senior
Nature Biotechnology 37 , 1249–1250

Rights & permissionsfor article Deerfield builds NYC campus to support life sciences startups . Opens in a new window.
News | 21 August 2019
Biotech giant helps itself without swallowing Galapagos whole
- Melanie Senior
Nature Biotechnology 37 , 1104–1105

Rights & permissionsfor article Biotech giant helps itself without swallowing Galapagos whole . Opens in a new window.
Special Features | 30 June 2020
The biopharmaceutical anomaly
- ...tightening and consolidation lie ahead? Melanie Senior investigates, with additional reporting...
- Melanie Senior
Nature Biotechnology 38 , 798–805

Rights & permissionsfor article The biopharmaceutical anomaly . Opens in a new window.
News | 11 June 2019
‘Scientific wellness’ searches for a business model
- Melanie Senior
Nature Biotechnology 37 , 705–706

Rights & permissionsfor article ‘Scientific wellness’ searches for a business model . Opens in a new window.
News | 3 January 2019
Checkpoint inhibitors go viral
- Melanie Senior
Nature Biotechnology 37 , 12–17

Rights & permissionsfor article Checkpoint inhibitors go viral . Opens in a new window.
News | 9 November 2018
FDA calls for subscription model to pay for anti-infectives
- Melanie Senior
Nature Biotechnology 36 , 1031–1031

Rights & permissionsfor article FDA calls for subscription model to pay for anti-infectives . Opens in a new window.
News | 6 June 2018
Beating the organ clock
- ...and offering new therapeutic opportunities. Melanie Senior reports.
- Melanie Senior
Nature Biotechnology 36 , 488–492

Rights & permissionsfor article Beating the organ clock . Opens in a new window.
News | 5 April 2018
Rollout of high-priced cell and gene therapies forces payer rethink
- Melanie Senior
Nature Biotechnology 36 , 291–292

Rights & permissionsfor article Rollout of high-priced cell and gene therapies forces payer rethink . Opens in a new window.
News | 7 June 2017
After Glybera's withdrawal, what's next for gene therapy?
- Melanie Senior
Nature Biotechnology 35 , 491–492

Rights & permissionsfor article After Glybera's withdrawal, what's next for gene therapy? . Opens in a new window.
News | 10 January 2018
Texas displays 'Silicon Valley' credentials to lure Brazilian biotechs
- Melanie Senior
Nature Biotechnology 36 , 12–13

Rights & permissionsfor article Texas displays 'Silicon Valley' credentials to lure Brazilian biotechs . Opens in a new window.
News | 1 August 2017
Google, Novartis back Medicxi's ambitions
- Melanie Senior
Nature Biotechnology 35 , 701–701

Rights & permissionsfor article Google, Novartis back Medicxi's ambitions . Opens in a new window.
News | 7 March 2017
Billion-dollar deals end eras of Ariad and Actelion
- Melanie Senior
Nature Biotechnology 35 , 183–184

Rights & permissionsfor article Billion-dollar deals end eras of Ariad and Actelion . Opens in a new window.
News | 5 April 2013
Biosimilars battle rages on, Amgen fights both sides
- Melanie Senior
Nature Biotechnology 31 , 269–270

Rights & permissionsfor article Biosimilars battle rages on, Amgen fights both sides . Opens in a new window.
News | 8 August 2013
Spreading biotech dollars around Washington
- ...all that money get them? Melanie Senior investigates.
- Melanie Senior
Nature Biotechnology 31 , 673–675

Rights & permissionsfor article Spreading biotech dollars around Washington . Opens in a new window.
News | 9 October 2014
The price of priority review: $67.5 million
- Melanie Senior
Nature Biotechnology 32 , 973–973

Rights & permissionsfor article The price of priority review: $67.5 million . Opens in a new window.
News | 6 November 2015
UK funding agencies weigh in on human germline editing
- Melanie Senior
Nature Biotechnology 33 , 1118–1119

Rights & permissionsfor article UK funding agencies weigh in on human germline editing . Opens in a new window.
News | 1 December 2013
Appetite for cheaper biologics spreads across the map
- Melanie Senior
Nature Biotechnology 31 , 1059–1060

Rights & permissionsfor article Appetite for cheaper biologics spreads across the map . Opens in a new window.
News | 9 January 2014
FDA halts then allows sales of Ariad's leukemia medication
- Melanie Senior
Nature Biotechnology 32 , 11–11

Rights & permissionsfor article FDA halts then allows sales of Ariad's leukemia medication . Opens in a new window.
News | 7 November 2014
Big-cap buying bonanza trickles down to small biotech
- Melanie Senior
Nature Biotechnology 32 , 1077–1078

Rights & permissionsfor article Big-cap buying bonanza trickles down to small biotech . Opens in a new window.
News | 9 June 2014
Sovaldi makes blockbuster history, ignites drug pricing unrest
- Melanie Senior
Nature Biotechnology 32 , 501–502

Rights & permissionsfor article Sovaldi makes blockbuster history, ignites drug pricing unrest . Opens in a new window.
News | 8 July 2015
Biotechs recoil at hedge fund manager's patent attacks
- Melanie Senior
Nature Biotechnology 33 , 680–681

Rights & permissionsfor article Biotechs recoil at hedge fund manager's patent attacks . Opens in a new window.
News | 10 June 2013
Family offices bolster early-stage financing
- Melanie Senior
Nature Biotechnology 31 , 473–474

Rights & permissionsfor article Family offices bolster early-stage financing . Opens in a new window.
News | 9 January 2015
Foundation receives $3.3-billion windfall for Kalydeco
- Melanie Senior
Nature Biotechnology 33 , 8–9

Rights & permissionsfor article Foundation receives $3.3-billion windfall for Kalydeco . Opens in a new window.
News | 10 September 2013
J&J courts biotech in clusters
- Melanie Senior
Nature Biotechnology 31 , 769–770

Rights & permissionsfor article J&J courts biotech in clusters . Opens in a new window.
News | 1 November 2013
Drugs with breakthrough status charm investors
- Melanie Senior
Nature Biotechnology 31 , 945–946

Rights & permissionsfor article Drugs with breakthrough status charm investors . Opens in a new window.
1 October 2015
Heart drug pushes outcome-based pricing plans
- Melanie Senior
Nature Reviews Drug Discovery 14 , 665–667

Rights & permissionsfor article Heart drug pushes outcome-based pricing plans . Opens in a new window.
News | 9 September 2014
Novartis signs up for Google smart lens
- Melanie Senior
Nature Biotechnology 32 , 856–856

Rights & permissionsfor article Novartis signs up for Google smart lens . Opens in a new window.
News | 6 March 2015
First US biosimilar edges towards market
- Melanie Senior
Nature Biotechnology 33 , 222–223

Rights & permissionsfor article First US biosimilar edges towards market . Opens in a new window.
Special Features | 27 May 2019
Nature Biotechnology’s academic spinouts of 2018
- ...Ken Garber, Esther Landhuis, Melanie Senior, Cormac Sheridan and Laura...
Nature Biotechnology 37 , 601–612

Rights & permissionsfor article <i>Nature Biotechnology</i>’s academic spinouts of 2018 . Opens in a new window.

Refine your results by…

Filters

Filter By:

Biotech companies prepare for COVID-19 downturn

Europe’s biotech renaissance

Amgen fined $762 million

Deerfield builds NYC campus to support life sciences startups

Biotech giant helps itself without swallowing Galapagos whole

The biopharmaceutical anomaly

‘Scientific wellness’ searches for a business model

Checkpoint inhibitors go viral

FDA calls for subscription model to pay for anti-infectives

Beating the organ clock

Rollout of high-priced cell and gene therapies forces payer rethink

After Glybera's withdrawal, what's next for gene therapy?

Texas displays 'Silicon Valley' credentials to lure Brazilian biotechs

Google, Novartis back Medicxi's ambitions

Billion-dollar deals end eras of Ariad and Actelion

Biosimilars battle rages on, Amgen fights both sides

Spreading biotech dollars around Washington

The price of priority review: $67.5 million

UK funding agencies weigh in on human germline editing

Appetite for cheaper biologics spreads across the map

FDA halts then allows sales of Ariad's leukemia medication

Big-cap buying bonanza trickles down to small biotech

Sovaldi makes blockbuster history, ignites drug pricing unrest

Biotechs recoil at hedge fund manager's patent attacks

Family offices bolster early-stage financing

Foundation receives $3.3-billion windfall for Kalydeco

J&J courts biotech in clusters

Drugs with breakthrough status charm investors

Heart drug pushes outcome-based pricing plans

Novartis signs up for Google smart lens

First US biosimilar edges towards market

Nature Biotechnology’s academic spinouts of 2018

Quick links

Refine your results by…

Filters ​

Filter By:

Search

Quick links

Filters